ClinicalTrials.gg
CompletedNCT04242498BE HEARD IIUpdated Oct 26, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 interventional study of Bimekizumab and Placebo in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 91 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
509
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
17th of 139
509 · median 45
Started
2020
with 15 others
Phase 3
24 of 161
3 open now
Registered
56th of 161
by date
Lead sponsor
6 of 161
UCB Biopharma SRL

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 17th largest by enrollment of the 139 interventional ones that give a count, is one of 16 that started in 2020, is one of 24 in phase 3, and was the 56th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Bimekizumab
  • UCB4940
  • HS
  • Hidradenitis Suppurativa
  • Acne inversa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 years of age, at the time of signing the . If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
  • Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
  • Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
  • Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
  • Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the guidance during the treatment period and for at least 20 weeks after the last dose of medicinal product (IMP)

Exclusion criteria

Exclusion Criteria:

  • Draining tunnel count of >20 at the Baseline Visit
  • Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
  • Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
  • Primary condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
  • Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of medicinal product (IMP)
  • Active infection or history of certain infection(s)
  • Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
  • Concurrent . Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
  • History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
  • Known to any components of bimekizumab or comparative drugs as stated in this protocol this protocol
  • Concomitant and prior medication restrictions
  • Myocardial infarction or stroke within the 6 months prior to the Screening Visit
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
  • Presence of moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
509 participants (actual)

Study arms

  • Experimental
    Bimekizumab dosing regimen 1

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 2

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 3

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.

    Drug: Bimekizumab

  • Placebo comparator
    Placebo Group

    Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: UCB4940

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16

    HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16

    HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

    Time frame: Week 16

  2. Percentage of Participants With Flare by Week 16

    Flare was defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event prior to experiencing a flare were treated as having experienced a flare at all flare assessments on and after the intercurrent event date. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

    Time frame: From Baseline to Week 16

  3. Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

    Time frame: Baseline, Week 16

  4. Absolute Change From Baseline in Worst Skin Pain Score at Week 16

    Absolute change from Baseline in worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

    Time frame: Baseline, Week 16

  5. Percentage of Participants Achieving Skin Pain Response at Week 16

    Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentages of participants shown do not account for model effects using logistic regression model.

    Time frame: Week 16

  6. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

  7. Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

  8. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

07

Results

Posted Dec 5, 2024

Participant flow

The study started to enroll participants in March 2020 and concluded in September 2022.

Initial Treatment Period: Week 0-16
Participant flow — Initial Treatment Period: Week 0-16
MilestonePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Started741442910000
Completed691332620000
Not completed511290000
Withdrew: Adverse event1190000
Withdrew: Lack of efficacy0010000
Withdrew: Protocol violation1010000
Withdrew: Lost to follow-up1030000
Withdrew: Consent withdrawn by subject, not due to ae28120000
Withdrew: Subject moved long distance from clinic (abroad)0010000
Withdrew: Withdrawn by investigator's decision0010000
Withdrew: Randomized, not treated0210000
Maintenance Treatment Period: Week 16-48
Participant flow — Maintenance Treatment Period: Week 16-48
MilestonePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Started00069133130131
Completed00061109107110
Not completed0008242321
Withdrew: Adverse event0000764
Withdrew: Lack of efficacy0000422
Withdrew: Protocol violation0000021
Withdrew: Lost to follow-up0002312
Withdrew: Consent withdrawn by subject, not due to ae000691011
Withdrew: Change in address-patient not wanting to continue0000100
Withdrew: Visits too time-consuming, only sfu will be done0000010
Withdrew: Subject relocated0000011

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16

HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 1632.2 (21.4 to 42.9)53.8 (45.4 to 62.1)52.0 (46.1 to 57.8)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.422 · 97.5% CI 1.221 to 4.804
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.003 · Odds ratio (or): 2.287 · 97.5% CI 1.220 to 4.291
SecondaryPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16

HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 1615.6 (7.2 to 24.0)33.7 (25.7 to 41.7)35.7 (30.1 to 41.3)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.007 · Odds ratio (or): 2.722 · 97.5% CI 1.182 to 6.267
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.007 · 97.5% CI 1.374 to 6.581
SecondaryPercentage of Participants With Flare by Week 16

Flare was defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event prior to experiencing a flare were treated as having experienced a flare at all flare assessments on and after the intercurrent event date. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.

Time frame:
From Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Flare by Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants With Flare by Week 1628.0 (17.6 to 38.4)23.6 (16.5 to 30.7)28.8 (23.5 to 34.1)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.497 · Odds ratio (or): 0.798 · 97.5% CI 0.378 to 1.683
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.868 · Odds ratio (or): 1.050 · 97.5% CI 0.541 to 2.041
SecondaryAbsolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
score on a scalePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16-3.2 ± 0.6-4.7 ± 0.5-4.6 ± 0.3
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · ANCOVA · p = <0.001 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Ls mean difference: -2.393 · 97.5% CI -3.920 to -0.867
  • Placebo vs BKZ Dosing Regimen 2 · ANCOVA · p = <0.001 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Ls mean difference: -2.309 · 97.5% CI -3.705 to -0.914
SecondaryAbsolute Change From Baseline in Worst Skin Pain Score at Week 16

Absolute change from Baseline in worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
score on a scalePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Absolute Change From Baseline in Worst Skin Pain Score at Week 16-0.36 ± 0.30-1.44 ± 0.24-1.83 ± 0.17
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · ANCOVA · p = 0.010 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Ls mean difference: -0.898 · 97.5% CI -1.684 to -0.113
  • Placebo vs BKZ Dosing Regimen 2 · ANCOVA · p = <0.001 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Ls mean difference: -1.265 · 97.5% CI -1.978 to -0.552
SecondaryPercentage of Participants Achieving Skin Pain Response at Week 16

Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentages of participants shown do not account for model effects using logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Skin Pain Response at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Skin Pain Response at Week 1610.9 (1.7 to 20.1)28.6 (19.5 to 37.8)31.8 (25.1 to 38.4)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.028 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Odds ratio (or): 3.273 · 97.5% CI 0.974 to 10.997
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.010 (Nominal p-value only due to the testing hierarchy failing on the flare outcome.) · Odds ratio (or): 3.756 · 97.5% CI 1.189 to 11.867
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study56.851.464.571.072.277.777.1
SecondaryPercentage of Participants With Serious Treatment-emergent Adverse Events During the Study

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study02.13.12.93.02.33.1
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study02.14.104.53.11.5

Adverse events

Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 71). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/74 (0%)0/74 (0%)18/74 (24.3%)
BKZ Dosing Regimen 10/142 (0%)3/142 (2.1%)40/142 (28.2%)
BKZ Dosing Regimen 20/290 (0%)9/290 (3.1%)101/290 (34.8%)
Placebo/BKZ Dosing Regimen 20/69 (0%)2/69 (2.9%)26/69 (37.7%)
BKZ Dosing Regimen 1/BKZ Dosing Regimen 10/133 (0%)4/133 (3%)49/133 (36.8%)
BKZ Dosing Regimen 2/BKZ Dosing Regimen 10/130 (0%)3/130 (2.3%)57/130 (43.8%)
BKZ Dosing Regimen 2/BKZ Dosing Regimen 20/131 (0%)4/131 (3.1%)64/131 (48.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Abdominal painGastrointestinal disorders0/740/1420/2901/690/1330/1300/131
AppendicitisInfections and infestations0/740/1420/2901/690/1330/1300/131
HidradenitisSkin and subcutaneous tissue disorders0/740/1422/2900/691/1331/1300/131
GastroenteritisInfections and infestations0/740/1420/2900/690/1331/1300/131
DepressionPsychiatric disorders0/740/1420/2900/690/1331/1300/131
Anal fissureGastrointestinal disorders0/740/1420/2900/690/1330/1301/131
Anal fistulaGastrointestinal disorders0/740/1420/2900/690/1330/1301/131
BartholinitisInfections and infestations0/740/1420/2900/690/1330/1301/131
Rash pustularInfections and infestations0/740/1420/2900/690/1330/1301/131
LymphoedemaVascular disorders0/740/1420/2900/690/1330/1301/131
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
HidradenitisSkin and subcutaneous tissue disorders5/7413/14223/2907/6916/13324/13015/131
Oral candidiasisInfections and infestations0/745/14224/2903/6911/13316/13014/131
HeadacheNervous system disorders7/747/14218/2903/697/1334/1307/131
NasopharyngitisInfections and infestations0/743/14211/2902/696/1338/13011/131
DiarrhoeaGastrointestinal disorders6/745/14218/2902/696/1334/1303/131
FolliculitisInfections and infestations0/745/1428/2902/695/1336/1309/131
Corona virus infectionInfections and infestations0/743/14211/2904/692/1337/1308/131
Upper respiratory tract infectionInfections and infestations1/740/1425/2904/697/1335/1303/131
EczemaSkin and subcutaneous tissue disorders1/741/1429/2904/695/1335/1303/131
Vulvovaginal candidiasisInfections and infestations0/748/1421/2901/692/1333/1303/131

Baseline characteristics

Baseline Characteristics refer to the RS which consisted of all study participants randomized into the study.

Age, Categorical
Age, Categorical(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
<=18 years071017
Between 18 and 65 years70135277482
>=65 years42410
Age, Continuous
Age, Continuous(Years)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Mean38.1 ± 13.235.2 ± 11.936.9 ± 12.336.6 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Female3177150258
Male4367141251
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
American Indian or Alaskan Native0011
Asian572234
Black5132240
Native Hawaiian or Other Pacific Islander0101
White64119232415
Other/mixed041216
Missing0022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Hispanic or Latino5101530
Not Hispanic or Latino69134274477
Missing0022
08

Study locations

91 sites
  • Hs0004 50162
    Fountain Valley, California 92708, United States
  • Hs0004 50196
    Thousand Oaks, California 91320, United States
  • Hs0004 50199
    Miami, Florida 33125, United States
  • Hs0004 50152
    Orange Park, Florida 32073, United States
  • Hs0004 50144
    Orlando, Florida 38219, United States
  • Hs0004 50184
    Pembroke Pines, Florida 33028, United States
  • Hs0004 50193
    Sandy Springs, Georgia 30328, United States
  • Hs0004 50223
    Savannah, Georgia 31419, United States
  • Hs0004 50164
    Skokie, Illinois 60077, United States
  • Hs0004 50234
    Plainfield, Indiana 46168, United States
  • Hs0004 50178
    Clarkston, Michigan 48346, United States
  • Hs0004 50105
    St Louis, Missouri 63110, United States
  • Hs0004 50197
    Henderson, Nevada 89052, United States
  • Hs0004 50159
    Portsmouth, New Hampshire 03801, United States
  • Hs0004 50200
    Verona, New Jersey 07044, United States
  • Hs0004 50237
    Albuquerque, New Mexico 87106, United States
  • Hs0004 50211
    Durham, North Carolina 27710, United States
  • Hs0004 50179
    Winston-Salem, North Carolina 27104, United States
  • Hs0004 50145
    Columbus, Ohio 43230, United States
  • Hs0004 50202
    Fairborn, Ohio 45324, United States
  • Hs0004 50150
    Philadelphia, Pennsylvania 19103, United States
  • Hs0004 50236
    Greenville, South Carolina 29615, United States
  • Hs0004 50084
    Johns Island, South Carolina 29425, United States
  • Hs0004 50148
    Pflugerville, Texas 78660, United States
  • Hs0004 30018
    Parkville, Australia
  • Hs0004 30014
    St Leonards, Australia
  • Hs0004 30009
    Westmead, Australia
  • Hs0004 40313
    Pleven, Bulgaria
  • Hs0004 40284
    Sofia, Bulgaria
  • Hs0004 40311
    Sofia, Bulgaria
  • Hs0004 40314
    Sofia, Bulgaria
  • Hs0004 40315
    Sofia, Bulgaria
  • Hs0004 40353
    Stara Zagora, Bulgaria
  • Hs0004 50172
    Cobourg, Canada
  • Hs0004 50135
    Edmonton, Canada
  • Hs0004 50174
    London, Canada
  • Hs0004 50189
    St. John's, Canada
  • Hs0004 50134
    Waterloo, Canada
  • Hs0004 50136
    Winnipeg, Canada
  • Hs0004 40063
    Prague, Czechia
  • Hs0004 40194
    Prague, Czechia
  • Hs0004 40245
    Antony, France
  • Hs0004 40321
    Auxerre, France
  • Hs0004 40129
    Bordeaux, France
  • Hs0004 40320
    La Rochelle, France
  • Hs0004 40247
    Lyon, France
  • Hs0004 40130
    Marseille, France
  • Hs0004 40404
    Reims, France
  • Hs0004 40403
    Saint-Etienne, France
  • Hs0004 40286
    Toulouse, France
  • Hs0004 40289
    Berlin, Germany
  • Hs0004 40326
    Berlin, Germany
  • Hs0004 40322
    Dessau, Germany
  • Hs0004 40356
    Dresden, Germany
  • Hs0004 40287
    Frankfurt am Main, Germany
  • Hs0004 40142
    Hamburg, Germany
  • Hs0004 40328
    Hanover, Germany
  • Hs0004 40250
    Lübeck, Germany
  • Hs0004 40254
    Debrecen, Hungary
  • Hs0004 40344
    Dublin, Ireland
  • Hs0004 20090
    Afula, Israel
  • Hs0004 20196
    Bunkyō City, Japan
  • Hs0004 20144
    Fukuoka, Japan
  • Hs0004 20195
    Kagoshima, Japan
  • Hs0004 20170
    Kurume, Japan
  • Hs0004 20190
    Kyoto, Japan
  • Hs0004 20033
    Nagoya, Japan
  • Hs0004 20152
    Nakagami-gun, Japan
  • Hs0004 20178
    Nishinomiya, Japan
  • Hs0004 20153
    Obihiro, Japan
  • Hs0004 20037
    Osaka, Japan
  • Hs0004 20154
    Sapporo, Japan
  • Hs0004 20171
    Sendai, Japan
  • Hs0004 20043
    tabashi City, Japan
  • Hs0004 40347
    Lodz, Poland
  • Hs0004 40293
    Rzeszów, Poland
  • Hs0004 40335
    Warsaw, Poland
  • Hs0004 40095
    Wroclaw, Poland
  • Hs0004 40333
    Wroclaw, Poland
  • Hs0004 40334
    Wroclaw, Poland
  • Hs0004 40159
    Barcelona, Spain
  • Hs0004 40267
    Barcelona, Spain
  • Hs0004 40298
    Granada, Spain
  • Hs0004 40268
    Madrid, Spain
  • Hs0004 40297
    Manises, Spain
  • Hs0004 40101
    Sabadell, Spain
  • Hs0004 40300
    Cardiff, United Kingdom
  • Hs0004 40339
    Leeds, United Kingdom
  • Hs0004 40113
    London, United Kingdom
  • Hs0004 40240
    Newcastle upon Tyne, United Kingdom
  • Hs0004 40338
    Northampton, United Kingdom
09

References and documents

Publications

  • Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I, Muller E, Pelligra CG, Ingram JR. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL(c)) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067. PubMed 40172122 ↗
  • Ingram JR, Lambert J, Ciaravino V, Rolleri R, Pansar I, Peterson L, Pelligra CG, Thorlacius L. Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data. Dermatol Ther (Heidelb). 2025 May;15(5):1093-1111. doi: 10.1007/s13555-025-01346-w. Epub 2025 Mar 28. PubMed 40153232 ↗
  • Shi VY, Ingram JR, Lev-Tov H, Schneider-Burrus S, Forman S, Porter ML, Hayama K, Thorlacius L, Lambert J, Vaux T, Lukowski B, Rolleri RL, Szepietowski JC. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatol Ther (Heidelb). 2025 Sep;15(9):2553-2570. doi: 10.1007/s13555-025-01465-4. Epub 2025 Jul 13. PubMed 40652434 ↗
  • Ingram JR, Fujita H, Gottlieb AB, Lev-Tov H, Prens E, Sayed CJ, Shi VY, Szepietowski JC, Takahashi K, Frew JW, Lambert J, Davis L, Oh T, Rolleri R, Saintmard MH, Orenstein LAV. Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. Pain Ther. 2025 Dec;14(6):1861-1878. doi: 10.1007/s40122-025-00779-7. Epub 2025 Oct 17. PubMed 41107641 ↗
  • Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II. J Eur Acad Dermatol Venereol. 2026 Feb 14. doi: 10.1111/jdv.70356. Online ahead of print. PubMed 41689425 ↗
  • Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15. PubMed 41248770 ↗
  • Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print. PubMed 42525209 ↗
  • Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available. PubMed 42482599 ↗
  • Daveluy S, Gottlieb AB, Augustin M, Lev-Tov H, Szepietowski JC, Horvath B, Porter ML, Hayama K, Lambert J, Tilt N, Lukowski B, Thorlacius L. Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II. Dermatol Ther (Heidelb). 2026 Jul;16(7):3315-3329. doi: 10.1007/s13555-026-01790-2. Epub 2026 Jun 5. PubMed 42247110 ↗
  • Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22. PubMed 38795716 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Nov 2021, 20 months.

Results were first posted in Dec 2024, 3 years after primary completion. A results delay was requested in Nov 2022.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Jan 27, 2020
StartActual
Mar 2, 2020
Primary completionActual
Nov 9, 2021
CompletionActual
Sep 28, 2022
Results delay requested
Nov 8, 2022
Results first posted
Dec 5, 2024
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co… PubMed 42525209 ↗; 1 more
across 2 updates, Sep 25, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Publications Results publication added: Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis… PubMed 42482599 ↗
    + 1 other change: verification date
  2. Sep 25, 2026
    Publications Results publication added: Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co… PubMed 42525209 ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04242498
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Mar 2, 2020
Primary completion
Nov 9, 2021
Completion
Sep 28, 2022
Results posted
Dec 5, 2024
Last update
Oct 26, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion